• Home
  • Contact Us
  • Sitemap
  • About Aveo
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
    • Careers
  • Product Candidates
    • Overview
    • Tivozanib (AV-951)
    • AV-299
    • AV-203
    • For Patients
  • Discovery Programs
    • Overview
  • Our Platform
    • Platform Overview
  • Partnering
    • Our Approach
    • Our Partners
    • Areas of Interest
  • Partnering
  • Overview
  • Press Releases
  • Events
  • Publications and Presentations

Media Contact:

Caton Lovett

Pure Communications

contact via email

(910) 232-7166

 

Press Releases

This part of our website contains archival information which should not be considered current and may no longer be accurate. We do not intend, and assume no obligation, to update, correct or otherwise modify any of these press releases for events that occur subsequent to the original release date. Please view our more recent press releases in order to receive the most current information.

 

  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2003

AVEO Initiates Enrollment in Phase 3 Clinical Trial Evaluating Tivozanib in Advanced Renal Cell Cancer

February 22, 2010

AVEO Pharmaceuticals Files Registration Statement for Initial Public Offering

December 16, 2009

AVEO's Triple VEGF Receptor Inhibitor Tivozanib in Combination with mTOR Inhibitor Demonstrates Anti-tumor Activity and Tolerability in Advanced Kidney Cancer; Preliminary Results Presented at AACR-NCI-EORTC Meeting

November 17, 2009

AVEO Pharmaceuticals Appoints William J. Slichenmyer, M.D., Sc.M., as Chief Medical Officer and Robert C. Young, M.D., to Board of Directors

September 16, 2009

AVEO Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference

September 4, 2009

AVEO Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference

August 4, 2009

AVEO's Tivozanib Demonstrates Anti-Tumor Activity in Engineered Lung Tumors Exhibiting Treatment Resistant Mutations

July 31, 2009

AVEO Pharmaceuticals to Present at IBC's New Frontiers in Cancer Drug Development Conference

July 30, 2009

OSI Pharmaceuticals and AVEO Pharmaceuticals Expand Oncology Discovery and Translational Research Collaboration

July 21, 2009

AVEO Pharmaceuticals Granted Patent for Protection of its Directed Complementation Technology

July 8, 2009

CEO of AVEO Pharmaceuticals Discusses Testing Stategies in a Life Sciences Report on NECN

June 18, 2009

AVEO Pharmaceuticals Granted Patent for Predictive Biomarker Used to Identify Human Tumors Likely to Respond to Notch Pathway Inhibition

June 17, 2009

AVEO Pharmaceuticals to Present at the 8th Annual Needham & Company Life Sciences Conference

June 5, 2009

AV-951 Demonstrates Prolonged Progression-Free Survival and Excellent Safety Profile in Patients with Advanced Kidney Cancer; Phase 2 Data Presented at ASCO

May 29, 2009

AVEO Pharmaceuticals to Present at Several Key Upcoming Medical and Industry Conferences

May 18, 2009

AVEO Pharmaceuticals' Scientific Advisory Board Members Recognized for Contributions to Cancer Research and Medicine

May 13, 2009

AVEO Announces Positive Finding for Triple VEGF Receptor Inhibitor AV-951 in Preclinical Model of Liver Cancer

April 21, 2009

AVEO Presents Novel HGF Model and Promising Preclinical Activity to Support Lead Antibody Agent SCH 900105 (AV-299)

April 19, 2009

Data on AVEO Pharmaceuticals' AV-951 in Liver Cancer Model and Preclinical Activity in SCH 900105 (AV-299) to be Presented at AACR 100th Annual Meeting

April 9, 2009

Breakthrough Preclinical Model for Human Cancer May Dramatically Improve Development of Effective Oncology Drugs; Data Published in PNAS

April 6, 2009

AVEO Pharmaceuticals to Present at the Future Leaders in the Biotech Industry Conference

March 26, 2009

AVEO and Biogen Idec Form Strategic Alliance for Development and Commercialization of ErbB3-Targeted Antibodies

March 24, 2009

AVEO and Biogen Idec Form Strategic Alliance for Development and Commercialization of ErbB3-Targeted Antibodies

March 23, 2009

AVEO Pharmaceuticals Selected to Present at InsideVenture's Debut Investor Conference March 25-26, Santa Barbara, California

March 23, 2009

AVEO Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference

March 11, 2009

AVEO Initiates Phase 1b/2a Clinical Trial of Novel, Triple VEGF Receptor Inhibitor AV-951 in Non-Small Cell Lung Cancer

March 10, 2009

AVEO Pharmaceuticals to Present at the Barclays Global Healthcare Conference

March 6, 2009

AVEO Pharmaceuticals' Oral Triple VEGF Receptor Inhibitor AV-951 Shows Robust Activity in Patents with Advanced Kidney Cancer

February 25, 2009

AVEO Initiates Phase 1b/2a Combination Trial of Novel, Triple VEGF Receptor Inhibitor - AV-951 in Advanced Breast Cancer

February 19, 2009

AVEO Pharmaceuticals to Present at Massachusetts Biotechnology Council

February 12, 2009

AVEO Pharmaceuticals Announces Oral Presentation of Data from AV-951 Phase 2 Clinical Trial at the 2009 Genitourinary Symposium

February 11, 2009

AVEO Pharmaceuticals to Present at 27th Annual J.P. Morgan Healthcare Conference

January 6, 2009

AVEO Pharmaceuticals to Present at the Lazard Capital Markets Fifth Annual Healthcare Conference

November 12, 2008

AVEO to Present at First Annual Boston Biotech R&D Conference

October 20, 2008

AVEO to Present at JMP Securities Healthcare Conference

September 30, 2008

AVEO Pharmaceuticals Initiates First Clinical Trial of Novel HGF Antagonist

September 23, 2008

AVEO Initiates Phase 1b Combination Trial of AV-951 with FOLFOX6 in Patients with Advanced Colorectal and other Gastrointestinal Cancers

August 25, 2008

Dyax Corp. and AVEO Pharmaceuticals Announce Antibody Library License Agreement

July 22, 2008

AVEO Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of AV-951 in Patients with Metastatic Renal Cell Carcinoma

May 29, 2008

AVEO Pharmaceuticals Granted Patent for Unique Genetic Screen to Identify Novel Cancer Drug Targets

May 22, 2008

AVEO Pharmaceuticals to Present at the 2008 Citi Investment Research Global Health Care Conference

May 15, 2008

AVEO Pharmaceuticals to Participate in Leerink Swann Solid Tumors Roundtable Conference

May 2, 2008

AVEO Pharmaceuticals' Novel Triple VEGF Receptor Inhibitor Shows Tumor Regression in Patients with Advanced Renal Cancer; Clinical Activity and Tolerability in other Solid Tumors including Colon and Lung Cancers

April 14, 2008

New Clinical Data on AVEO Pharmaceuticals' Investigational Triple VEGFR Small Molecule Inhibitor AV-951 to be Presented at AACR Annual Meeting

April 8, 2008

AVEO Pharmaceuticals to Present at the Future Leaders in the Biotech Industry Conference

March 20, 2008

AVEO Pharmaceuticals to Present at the Future Leaders in the Biotech Industry Conference

March 20, 2008

AVEO Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference

March 12, 2008

AVEO Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference

February 5, 2008

AVEO Initiates Phase 1b Combination Clinical Trial of Novel Triple VEGF Receptor Inhibitor AV-951 in Metastatic Renal Cell Carcinoma

January 31, 2008

AVEO Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

January 30, 2008

AVEO Pharmaceuticals Appoints Kenneth M. Bate to Board of Directors

January 3, 2008

AVEO Pharmaceuticals to Present at 26th Annual JPMorgan Healthcare Conference

January 2, 2008

AVEO Pharmaceuticals and Lilly Sign Collaboration for Clinical Drug Response Project

December 4, 2007

AVEO Pharmaceuticals to Present at Lazard Capital Markets 4th Annual Healthcare Conference

November 20, 2007

Preclinical Data Published in Cancer Science Show AVEO's Novel Oral EGFR Inhibitor AV-412 Effective in Drug-Resistant Cancers

November 13, 2007

Results from Phase 1 Study of AVEO's Novel Triple VEGF Receptor Inhibitor AV-951 Show 100% of Renal Cell Cancer Patients Achieved Partial Response or Stable Disease

November 6, 2007

AVEO Pharmaceuticals Appoints David Johnston as CFO

October 30, 2007

AVEO Pharmaceuticals to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

October 30, 2007

AVEO Pharmaceuticals to Utilize Peptech's Breakthrough Technology to "Humanise" Internal Drug Candidates

October 2, 2007

OSI Pharmaceuticals and AVEO Pharmaceuticals Enter into an Oncology Drug Discovery and Translational Research Collaboration

October 2, 2007

AVEO Announces Successful Completion of Discovery Agreement for Novel Cancer Drugs

August 9, 2007

AVEO featured in Boston Globe

July 2, 2007

AVEO Featured in Xconomy.com

July 2, 2007

AVEO PHARMACEUTICALS CEO TUAN HA-NGOC RECEIVES ERNST & YOUNG NEW ENGLAND ENTREPRENEUR OF THE YEAR AWARD

June 18, 2007

AVEO Pharmaceuticals Closes $53 Million in Series D Funding

May 3, 2007

Finalists for the Ernst & Young Entrepreneur Of The Year Award in New England Announced

April 25, 2007

Novel Human Tissue Transgenic Cancer Model May Offer Significant Advance Toward Accurately Modeling Human Cancer

April 18, 2007

AVEO Presents Preclinical Efficacy Data on AV-412, A Novel Oral Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and Drug-resistant Lung Cancer

April 17, 2007

AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical Pipeline to be featured at AACR

April 12, 2007

AVEO enters into Worldwide License and Development Agreement with Schering-Plough for AV-299, AVEO's Novel Anti-HGF Antibody

April 4, 2007

AVEO acquires Clinical Stage Anti-Cancer Compound from Kirin

January 4, 2007

AVEO Pharmaceuticals initiates Clinical Development of AV-412 in Cancer Patients with Advanced Solid Tumors

October 23, 2006

AVEO and XOMA Enter Into Supply Agreement for AVEO's Novel Anti-HGF Antibody

September 28, 2006

AVEO Pharmaceuticals selected to receive 'Pharmaceutical Industry Standard of Excellence' WebAward by Web Marketing Association

September 27, 2006

XOMA and AVEO Announce Agreement to Apply Human Engineering Technology to AV-299, AVEO's Novel Anti-HGF Antibody

April 27, 2006

AVEO Pharmaceuticals Presents a Novel System for the Generation of Fully Human Breast Tumors in Mice at AACR 2006

April 5, 2006

AV-412 Preclinical Efficacy Data Presented at AACR 2006

April 4, 2006

Hercules Provides $15.0M Financing to AVEO Pharmaceuticals, Inc., a Biopharmaceutical Company Focused on the Discovery and Development of Novel Cancer Medicines

March 30, 2006

AVEO Pharmaceuticals Appoints John Ryan, Ph.D., M.D., As Chief Medical Officer

March 30, 2006

AVEO Pharmaceuticals acquires rights to novel anti-cancer compound from Mitsubishi Pharma Corporation

January 5, 2006

AVEO Pharmaceuticals and Merck Sign Collaboration for Clinical Drug Response Prediction

November 1, 2005

GenPath Pharmaceuticals Becomes AVEO Pharmaceuticals

March 1, 2005

GenPath Pharmaceuticals and Merck Enter Into Potential $100 Million Deal For The Discovery of Novel Cancer Drugs

November 17, 2003

GenPath Pharmaceuticals Announces Issuance of Fundamental U.S. Patent Covering its Proprietary Cancer Models

October 29, 2003

GenPath Pharmaceuticals Raises $42.7 Million in Series B Funding

October 1, 2003

 
 

© 2010 AVEO Pharmaceuticals, Inc. All rights reserved.

  • Home
  • Contact Us
  • Sitemap
  • Terms
  • Privacy
  •   |  
  • For Patients
  • For Physicians
  • Careers